Research programme: radiolabeled ACE diagnostics - Molecular Insight Pharmaceuticals

Drug Profile

Research programme: radiolabeled ACE diagnostics - Molecular Insight Pharmaceuticals

Alternative Names: MIP-190

Latest Information Update: 23 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Class Diagnostic agents; Imaging agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 25 Mar 2008 Preclinical development is ongoing
  • 08 Feb 2007 Preclinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top